{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:01:51Z","timestamp":1790874111138,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clml.2026.07.005","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:56:56Z","timestamp":1783922216000},"page":"633-639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions| Mediastinal Gray-zone Lymphoma: Novel Biologic Insights and Updates on How Best to Approach This Rare Entity"],"prefix":"10.1016","volume":"26","author":[{"given":"Gonca","family":"Ozcan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Roswarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieron","family":"Dunleavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.07.005_bib0001","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.07.005_bib0002","first-page":"1229","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.07.005_bib0003","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.3324\/haematol.2024.285266","article-title":"A targeted gene signature stratifying mediastinal gray zone lymphoma into classical Hodgkin lymphoma-like or primary mediastinal B-cell lymphoma-like subtypes","volume":"109","author":"Gargano","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.07.005_bib0004","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/PAS.0000000000001198","article-title":"Gray-zone lymphoma between cHL and large B-cell lymphoma: a histopathologic series from the LYSA","volume":"43","author":"Sarkozy","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2026.07.005_bib0005","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2017"},{"key":"10.1016\/j.clml.2026.07.005_bib0006","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/2643-3230.BCD-20-0009","article-title":"Gene expression profiling of mediastinal gray zone lymphoma and its relationship to primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma","volume":"1","author":"Pittaluga","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.clml.2026.07.005_bib0007","first-page":"1765","article-title":"Mutational landscape of gray zone lymphoma","volume":"137","author":"Sarkozy","year":"2021","journal-title":"Blood J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.07.005_bib0008","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/bloodadvances.2020001923","article-title":"Gene expression profiling of gray zone lymphoma","volume":"4","author":"Sarkozy","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.005_bib0009","first-page":"863","article-title":"EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment","volume":"126","author":"Nicolae","year":"2015","journal-title":"Blood J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.07.005_bib0010","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1182\/blood-2014-03-564906","article-title":"A prospective study of mediastinal gray-zone lymphoma","volume":"124","author":"Wilson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.005_bib0011","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.clml.2025.02.013","article-title":"SOHO State of the art updates and next questions|latest advances in the management of primary mediastinal B-cell lymphoma","volume":"25","author":"Lap","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.07.005_bib0012","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bjh.14226","article-title":"Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma","volume":"179","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.07.005_bib0013","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3324\/haematol.2016.152256","article-title":"Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association","volume":"102","author":"Sarkozy","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.07.005_bib0014","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/bjh.14174","article-title":"How I manage patients with grey zone lymphoma","volume":"174","author":"Kritharis","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.07.005_bib0015","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ajh.24082","article-title":"Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort","volume":"90","author":"Evens","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.07.005_bib0016","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/modpathol.2011.116","article-title":"Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations","volume":"24","author":"Eberle","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2026.07.005_bib0017","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/bloodadvances.2017009472","article-title":"Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL","volume":"1","author":"Pilichowska","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.005_bib0018","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1182\/hematology.2025000748C","article-title":"All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents?","volume":"2025","author":"Sarkozy","year":"2025","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2026.07.005_bib0019","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.07.005_bib0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.clml.2024.07.019","article-title":"Incidence of central nervous system relapse in primary mediastinal large B-cell lymphoma: implications for central nervous system prophylaxis","volume":"25","author":"Okcu","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.07.005_bib0021","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2007.12.5088","article-title":"CNS involvement in Hodgkin's lymphoma","volume":"25","author":"Re","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.07.005_bib0022","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2006.10.1691","article-title":"Hodgkin's lymphoma involving the CNS","volume":"25","author":"Morawa","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.07.005_bib0023","first-page":"1","article-title":"Into the gray-zone: update on the diagnosis and classification of a rare lymphoma","volume":"13","author":"Egan","year":"2020"},{"key":"10.1016\/j.clml.2026.07.005_bib0024","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/01.pas.0000180856.74572.73","article-title":"Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma","volume":"29","author":"Traverse-Glehen","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2026.07.005_bib0025","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjh.16331","article-title":"Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma\/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases","volume":"189","author":"Aussedat","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.07.005_bib0026","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2026.07.005_bib0027","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.005_bib0028","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.005_bib0029","first-page":"549","article-title":"Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells","volume":"60","author":"Joos","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2026.07.005_bib0030","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clml.2026.07.005_bib0031","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1182\/blood.V87.4.1571.bloodjournal8741571","article-title":"Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene","volume":"87","author":"Joos","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.005_bib0032","first-page":"2659","article-title":"The molecular pathogenesis of primary mediastinal large B-cell lymphoma","volume":"118","author":"Steidl","year":"2011","journal-title":"Blood J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.07.005_bib0033","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/bloodadvances.2017009472","article-title":"Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL","volume":"1","author":"Pilichowska","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.005_bib0034","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3324\/haematol.2010.033167","article-title":"Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin\u2019s lymphoma and primary mediastinal large B-cell lymphoma","volume":"96","author":"Eberle","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.07.005_bib0035","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.07.005_bib0036","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ijrobp.2025.08.012","article-title":"The role of radiation therapy in the management of gray zone lymphoma","volume":"123","author":"Saifi","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2026.07.005_bib0037","series-title":"NCCN Clinical Practice Guidelines in Oncology. B-Cell Lymphoma. Version 4.2026","year":"2026"},{"key":"10.1016\/j.clml.2026.07.005_bib0038","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc1704767","article-title":"PD-1 blockade in mediastinal gray-zone lymphoma","volume":"377","author":"Melani","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.07.005_bib0039","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00277-017-3179-3","article-title":"Favorable response of relapsed\/refractory gray-zone lymphoma to brentuximab vedotin","volume":"97","author":"Li","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.07.005_bib0040","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.005_bib0041","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.005_bib0042","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1182\/bloodadvances.2023010254","article-title":"Nivolumab combined with brentuximab vedotin for R\/R primary mediastinal large B-cell lymphoma: a 3-year follow-up","volume":"7","author":"Zinzani","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.005_bib0043","first-page":"2780","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory mediastinal gray zone lymphoma","volume":"141","author":"Santoro","year":"2023","journal-title":"Blood J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.07.005_bib0044","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41375-024-02213-x","article-title":"Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study","volume":"38","author":"Chiappella","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.07.005_bib0045","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.005_bib0046","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.07.005_bib0047","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/ajh.70033","article-title":"CD19 CAR T-cell therapy for primary mediastinal large B-cell lymphoma: a CIBMTR analysis","volume":"100","author":"Gauthier","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.07.005_bib0048","article-title":"Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas","volume":"106","author":"Svoboda","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.07.005_bib0049","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO-24-01373","article-title":"Omission of radiotherapy in primary mediastinal B-cell lymphoma: IELSG37 trial results","volume":"42","author":"Martelli","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:16:46Z","timestamp":1790871406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026002107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2152265026002107"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions| Mediastinal Gray-zone Lymphoma: Novel Biologic Insights and Updates on How Best to Approach This Rare Entity","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}